Accellix

AstraZeneca and Moffitt Cancer Center are partnering to accelerate the development of CAR-T and TCR-T cell therapies. Key areas of focus will be on advancing solid tumor cell therapies and addressing cell therapy development challenges to expand their reach to more patients in the United States and beyond. #oncology #celltherapy https://lnkd.in/e_gjPrmZ

Just under a week to go until Alliance for Regenerative Medicine’s #CGMesa24 in sunny Phoenix, AZ. Rey (Reut) Mali and Michael Sherriff are attending and look forward to exploring new opportunities for collaboration that will help shape the future of CGT. Learn how the Accellix automated flow cytometry platform is disrupting cell therapy QC. Schedule a 1:1 meeting during the event: https://lnkd.in/gPi65Wxn

Carisma Therapeutics and Moderna expand their collaboration to co-develop two in vivo CAR-M therapies for autoimmune diseases. The combination of Carisma's proprietary CAR-M technology and Moderna's mRNA/LNP platform will be used to harness the power of macrophages to treat diseases beyond oncology targets. #macrophages #autoimmunedisease https://lnkd.in/dtvU5cV6

In vivo CAR-Ts continue to gain momentum in the field! Nona Biosciences and Umoja Biopharma are joining forces to develop novel in vivo CAR-T cell therapy drug candidates for oncology and autoimmunity. This collaboration will leverage Nona’s fully human heavy chain only antibody (HCAb) technology, which can reduce immunogenicity and enhance CAR design with compact size, simplified structure, and precisely calibrated binding properties. https://lnkd.in/gZN3MEFt

Accellix is pleased to welcome Greg Hamilton as our new CEO and member of the Board! With his extensive life sciences leadership experience, Greg will play a key role in driving growth into the cell therapy and blood banks markets. Congratulations, Greg! https://lnkd.in/dZhtvVXV

?REMINDER: CAR-TCR Panel discussion today at 2:25PM Join Christian Aguilera-Sandoval from Accellix, Melissa Van Pel from NecstGen, and Félix A MONTERO-JULIAN PhD, from bioMérieux for a panel discussion on "Strategic Solutions for Rapid Identity and Purity Testing Throughout the CAR-T Manufacturing Process," moderated by Tristan Pritchard-Meaker from NecstGen that will focus on: ? Benefits of early partnering for CAR-T lentiviral vector design optimization and assay development. ? Incorporating automated flow cytometry throughout the CAR-T manufacturing process. ? The importance of sterility safety tests for CAR-T products. Don’t miss out on these valuable insights! CAR-TCR Summit Series

?REMINDER: The CAR-TCR Summit Series Welcome Reception and poster session is happening tonight between 6:00PM - 7:30PM EDT. Amanda Trent will be available at the Accellix poster #2 "Implementing Dynamic Automated Flow Cytometric Analysis for Rapid Cell Therapy Manufacturing QC”. Stop by and say hello! See you there! #CellTherapyQC #flowcytometry

The Accellix team is looking forward to the 9th CAR-TCR Summit in Boston next week! We have some exciting events lined up that you don't want to miss, including: ? Tuesday Sept 17 at 6:30PM:?Poster presentation "Implementing Dynamic Automated Flow Cytometric Analysis for Rapid Cell Therapy Manufacturing QC"?with Amanda Trent. ? Thursday Sept 19 at 2:25PM: Join Christian Aguilera-Sandoval from?Accellix?and collaborators Melissa Van Pel?from?NecstGen, and Félix A MONTERO-JULIAN PhD?from?bioMérieux?for a panel discussion on "Strategic Solutions for Rapid Identity and Purity Testing Throughout the CAR-T Manufacturing Process". Moderated by Tristan Pritchard-Meaker from NecstGen. ?? Be sure to stop by our booth #23 during the event?to speak with our experts Hiren Patel, Rey (Reut) Mali, Michael Sherriff, Timothy Sheets, M.S., Ph.D. and Amanda Trent. Learn about the applications of the Accellix platform throughout the CAR-T manufacturing process and how algorithm-based automated analysis can streamline your cell therapy manufacturing QC workflows.? Check out the schedule below for full event details. See you in Boston! CAR-TCR Summit Series: https://ter.li/mcx1tq

Live from Lisbon at #ATE24! The conference is in full swing, and it's the perfect time to visit the Accellix booth! Stop by and connect with Hiren Patel and Michael Sherriff to learn how the Accellix automated flow cytometry platform can transform #celltherapy QC—come see us before the event ends!

Caribou Biosciences has received FDA Fast Track designation for two of its allogeneic CAR-T cell therapies: CB-010 for refractory systemic lupus erythematosus (SLE) and CB-012 for relapsed/refractory acute myeloid leukemia (r/r AML). Developed using Caribou’s next-generation CRISPR platform, these therapies aim to deliver effective, off-the-shelf treatment options for patients affected by these diseases. https://lnkd.in/gj_qZr39